Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Detailed Positive ABRAXANE Phase III Data Released

December 8th, 2003

Detailed Positive ABRAXANE Phase III Data Released

Abstract:
American Pharmaceutical Partners, Inc. and ABRAXIS Oncology, the proprietary drug division of APP, today announced positive results of the randomized, controlled Phase III clinical trial in patients with metastatic breast cancer comparing the investigational product ABRAXANE(TM) to the Cremophor® solvent-based TAXOL®. Patients with metastatic breast cancer receiving the solvent-free nanoparticle paclitaxel, ABRAXANE achieved almost a doubling of the tumor response rate when compared to those patients receiving Bristol-Myers Squibb's TAXOL®.

Source:
APP

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Tracking a Killer: UCSB, UCSD and SBP researchers trace the complex and variable pathways to the deadly condition known as sepsis October 12th, 2018

Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018 October 11th, 2018

Nano Pharmaceutical Developed to Target Cancer Cells October 10th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project